DIAGNOS Receives Health Canada Medical Device Licence for CARA System, Bringing AI-Assisted Retinal Image Analysis to Canadian Optometrists

This section is Partnership Content suppliedThe content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire Article contentBROSSARD, Quebec, July 27, 2026 (GLOBE NEWSWIRE) — Diagnos Inc.

(“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, is pleased to announce that, on July 23, 2026, it has received a Health Canada Medical Device Licence authorizing the commercialization of its CARA System in Canada.Sign In or Create an AccountEmail AddressContinueor View more offersArticle contentCARA System technology integrates AI-powered analysis modules within a single clinician-controlled workflow:Article contentWe apologize, but this video has failed to load.Try refreshing your browser, ortap here to see other videos from our team.

Article contentArticle contentCARA-AMDdetect – Age-related macular degeneration detectionCARA-DR – Diabetic retinopathy detectionCARA-MVA – Retinal microvascular analysisCARA-Enhancement – Advanced retinal image enhancementCARA-CWS – Clinician WorkSpace for annotationsArticle contentTop StoriesGet the latest headlines, breaking news and columns.There was an error, please provide a valid email address.Sign UpBy signing up you consent to receive the above newsletter from Postmedia Network Inc.

Thanks for signing up!A welcome email is on its way. If you don't see it, please check your junk folder.

The next issue of Top Stories will soon be in your inbox.We encountered an issue signing you up. Please try againInterested in more newsletters?

Browse here.Article contentBy combining image enhancement, explainable AI findings, fundus indicators and retinal vascular analytics, CARA helps clinicians unlock more clinically relevant information from every fundus photograph while ensuring that the optometrist remains in full control of every clinical decision.Article contentTo our knowledge, CARA is one the first Canadian AI-retinal image analysis platform developed specifically for the Optometry sector to be granted a Class II medical device licence by Health Canada.

This authorization allows us to fully deliver our services to IRIS The Visual Group (refer to announcement dated June 7, 2022) and to deploy our marketing strategy to address the Canadian optometry market.Article contentNowadays, retina of the eye photography is routinely incorporated into optometry clinical workflows practices from both independent optometry practices and major eye care networks. Using advanced image enhancement and explainable artificial intelligence, CARA System uses every pixel of a fundus photograph to provide the optometrist with objective analytical insights related to retinal conditions that may not have been readily apparent.

Article contentArticle content“For more than a decade, DIAGNOS has been working with AI for retinal image analysis through collaborations with clinicians and healthcare organizations around the world, driven by one mission – to help prevent avoidable blindness,” said André Larente, President and Chief Executive Officer of DIAGNOS.“Article content“Health Canada’s authorization of the CARA System is an important achievement not only for DIAGNOS, but also for Quebec’s innovation ecosystem,” said Philippe Couillard, chairman of the board of directors of DIAGNOS. “Successfully developing artificial intelligence for regulated medical devices requires scientific excellence, clinical rigor and exceptional perseverance.

I am proud that Quebec-based companies can develop world-class medical technologies, meet one of the world’s most demanding regulatory standards, and compete successfully on the international stage.”Article content“We are excited to bring CARA System to Canadian optometrists, unlocking the full clinical value of every fundus image through explainable AI. CARA System transforms routinely acquired retinal images into deeper clinical insights while ensuring clinicians remain at the center of every clinical decision,” said Yves-Stephane Couture, Chief Operating Officer of DIAGNOS.

Advertisement 1This advertisement has not loaded yet.Trending Posthaste: Canadians' biggest source of wealth is losing ground and that's dragging down the economy News Subscriber only. About $500 billion in natural gas lies off Newfoundland's coast.

Can Canada tap it? Subscriber only Oil & Gas Advertisement 1Story continues belowThis advertisement has not loaded yet, but your article continues below. Ontario woman awarded $400,000 over husband's decades-long abuse in legal first Legal Post Canadians' economic pessimism is fading despite trade war, Nanos poll says Economy The market's biggest risk isn't AI or tariffs.

It’s something stock investors may overlook Investor Advertisement 2AdvertisementThis advertisement has not loaded yet, but your article con